Esperion Therapeutics (ESPR) Net Cash Flow (2012 - 2026)
Esperion Therapeutics (ESPR) posted Net Cash Flow of -$11.7 million for Q1 2026, down 115.51% on a QoQ basis from $75.4 million in Q4 2025, and up 61.19% year-over-year from -$7.3 million in Q1 2025.
Esperion Therapeutics (ESPR) Net Cash Flow (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Net Cash Flow history runs 15 years deep, the most recent figure standing at -$11.7 million for Q1 2026.
- Quarterly Net Cash Flow rose 61.19% year-over-year to -$11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 137.08% YoY) and the FY2025 annual result came in at $23.1 million, down 63.06% from the prior year.
- Net Cash Flow was -$11.7 million for Q1 2026 at Esperion Therapeutics, down from $75.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $144.4 million in Q1 2024 and bottomed at -$84.6 million in Q4 2022.
- A 5-year average of -$6.0 million and a median of -$23.6 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 2299.2% — and 2025, when it soared 171275.0%.
- Esperion Therapeutics' Net Cash Flow stood at -$84.6 million in 2022, then soared by 61.49% to -$32.6 million in 2023, then soared by 100.14% to $44000.0 in 2024, then surged by 171275.0% to $75.4 million in 2025, then tumbled by 115.51% to -$11.7 million in 2026.
- Business Quant data shows ESPR's Net Cash Flow at -$11.7 million in Q1 2026, $75.4 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -11.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.69 Mn |
| Mar 31, 2026 | -11.69 Mn |
| Dec 31, 2025 | 75.41 Mn |
| Dec 31, 2025 | 75.41 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Jun 30, 2025 | -28.57 Mn |
| Jun 30, 2025 | -28.57 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Dec 31, 2024 | 44,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Sep 30, 2024 | -44.59 Mn |
| Sep 30, 2024 | -44.59 Mn |
| Jun 30, 2024 | -37.31 Mn |
| Jun 30, 2024 | -37.31 Mn |
| Mar 31, 2024 | 144.36 Mn |
| Mar 31, 2024 | 144.36 Mn |
| Dec 31, 2023 | -32.59 Mn |
| Dec 31, 2023 | -32.59 Mn |